Gliatech guilty plea
This article was originally published in The Gray Sheet
Adcon-L developer faces up to $1.2 mil. in fines and a five-year probation under an agreement with the Justice Department. Gliatech pleads guilty to six misdemeanors, including failure to submit Medical Device Reports to FDA, adulteration of a medical device, and the submission of false reports to FDA. The agency currently is reviewing the company's Application Integrity Policy (AIP) corrective action plan (CAP), which was submitted in November 2001. The anti-adhesion product was taken off the U.S. market in January 2001 and is only available internationally...
You may also be interested in...
Purell Battling Class Actions Over Disease Claims While World Scrambles To Increase Hand Sanitizer Supplies
Leading chemical firms, beauty and consumer health companies, even distilleries and medical marijuana cultivators are adapting operations to meet global demand for hand sanitizers amid the COVID-19 pandemic. Meanwhile, plaintiff’s attorneys are busy with multiple class actions against Purell manufacturer GOJO Industries for alleged false advertising following a January warning letter to the firm from the US FDA.
FDA's Emergency Use Authorization for Malaria Drugs Could Hinder Trials of Other COVID-19 Treatments
Questions linger about the role the White House played in pushing the EUA, which comes with large product donations from Bayer and Sandoz that are expected to alleviate supply chain pressures for the drugs.
FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.